Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and
U.S. Food and Drug Administration (FDA) Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal MelanomaEnrollment Complete in Phase 2 Trial in Choroidal Melanoma Using Suprachoroidal Route of AdministrationBOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biot...